Welcome to GenPrice! Check out our latest updates.

Shopping Cart (0)

Your cart is empty

Add some products to get started!

Elimusertib (hydrochloride)

Elimusertib (BAY 1895344) hydrochloride is a potent, orally active and selective ATR inhibitor with an IC50 of 7 nM. Elimusertib hydrochloride has anti-tumor activity[1][2]. Elimusertib hydrochloride can be used for the research of solid tumors and lymphomas[3].

Product Specifications

Product Name Alternative

BAY 1895344 (hydrochloride)

UNSPSC

12352005

Target

ATM/ATR

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; PI3K/Akt/mTOR

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/BAY-1895344_hydrochloride.html

Concentration

10mM

Purity

99.85

Solubility

DMSO : 50 mg/mL (ultrasonic) |H2O : 50 mg/mL (ultrasonic)

Smiles

CN1N=CC=C1C2=C(C=CN=C3C4=CC=NN4)C3=NC(N5[C@H](C)COCC5)=C2.[H]Cl

Molecular Formula

C20H22ClN7O

Molecular Weight

411.89

References & Citations

[1]Ulrich T. Luecking, et al. Abstract 983: Identification of potent, highly selective and orally available ATR inhibitor BAY 1895344 with favorable PK properties and promising efficacy in monotherapy and combination in preclinical tumor models. Cancer Research. July 2017 Volume 77, Issue 13 Supplement.|[2]Antje Margret Wengner, et al. Abstract 836: ATR inhibitor BAY 1895344 shows potent anti-tumor efficacy in monotherapy and strong combination potential with the targeted alpha therapy Radium-223 dichloride in preclinical tumor models. Cancer Research. July 2017 Volume 77, Issue 13 Supplement|[3]Ulrich Lücking, et al. Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor Models. J Med Chem. 2020 Jul 9;63 (13) :7293-7325.

Shipping Conditions

Room Temperature

Storage Conditions

4°C (Powder, sealed storage, away from moisture)

Scientific Category

Reference compound1

Clinical Information

Phase 2

Isoform

ATR

Citation 01

Cancer Res. 2022 Mar 15;82 (6) :1013-1024.|RSC Adv. 2025 Jun 16;15 (26) :20385-20396.|Biochem Pharmacol. 2023 May:211:115494.|bioRxiv. 2025 Sep 30.|Cell Rep Med. 2025 May 6:102129.|EMBO Rep. 2024 Mar;25 (3) :1469-1489.|Exp Mol Med. 2025 Feb;57 (1) :167-183.|J Med Chem. 2024 Feb 22;67 (4) :2349-2368.|Mol Cell Biol. 2025;45 (3) :99-115.|Nat Commun. 2024 Oct 24;15 (1) :9195.|Research Square Preprint. 2023 Jun 9.|Research Square Preprint. 2023 May 17.|Research Square Preprint. 2023 Nov 20.

Available Sizes

More Discoveries

Explore Other Products

Browse additional items from our catalog

H3F3B  polyclonal antibody
BS74418 50ul

H3F3B polyclonal antibody

Sign In for Pricing
View Details
Mouse Pole Pre-designed siRNA Set A
SI110861A 1 Each

Mouse Pole Pre-designed siRNA Set A

Sign In for Pricing
View Details
Canine WDR46 ELISA KIT
ELI-17496d 96 Tests

Canine WDR46 ELISA KIT

Sign In for Pricing
View Details
HPD Antibody
A25517-100UL 100 µL

HPD Antibody

Sign In for Pricing
View Details
Alpha 1 Acid Glycoprotein Antibody
7010-30T 30 µg

Alpha 1 Acid Glycoprotein Antibody

Sign In for Pricing
View Details
Ligupurpuroside B
M38908-01 100 mg

Ligupurpuroside B

Sign In for Pricing
View Details